Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report

Approximately 15–20% of breast cancer patients are epidermal growth factor receptor 2 (HER2)-positive, and about half of these are also hormone receptor (HR)-positive. The mainstay treatment for HER2-positive/HR-positive patients is anti-HER2 treatment combined with chemotherapy. However, many patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Ning, Liu, Liping, Tian, Can, Hu, Zheyu, Ouyang, Quchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422146/
https://www.ncbi.nlm.nih.gov/pubmed/34532493
http://dx.doi.org/10.21037/atm-21-3978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422146/
https://www.ncbi.nlm.nih.gov/pubmed/34532493
http://dx.doi.org/10.21037/atm-21-3978

Ejemplares similares